[Federal Register Volume 87, Number 152 (Tuesday, August 9, 2022)]
[Notices]
[Pages 48484-48486]
[FR Doc No: 2022-17056]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2022-N-1694]

Determination That AVC (Sulfanilamide) Vaginal Cream, 15%, and
Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety
or Effectiveness

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) has
determined that the drug products listed in this document were not
withdrawn from sale for reasons of safety or effectiveness. This
determination means that FDA will not begin procedures to withdraw
approval of abbreviated new drug applications (ANDAs) that refer to
these drug products, and it will allow FDA to continue to approve ANDAs
that refer to the products as long as they meet relevant legal and
regulatory requirements.

FOR FURTHER INFORMATION CONTACT: Stacy Kane, Center for Drug Evaluation
and Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 51, Rm. 6236, Silver Spring, MD 20993-0002,<PHONE_NUMBER>,
[email protected].

SUPPLEMENTARY INFORMATION: Section 505(j) of the Federal Food, Drug,
and Cosmetic Act (FD&C Act) (21 U.S.C. 355(j)) allows the submission of
an ANDA to market a generic version of a previously approved drug
product. To obtain approval, the ANDA applicant must show, among other
things, that the generic drug product: (1) has the same active
ingredient(s), dosage form, route of administration, strength,
conditions of use, and (with certain exceptions) labeling as the listed
drug, which is a version of the drug that was previously approved, and
(2) is bioequivalent to the listed drug. ANDA applicants do not have to
repeat the extensive clinical testing otherwise necessary to gain
approval of a new drug application (NDA).
    Section 505(j)(7) of the FD&C Act requires FDA to publish a list of
all approved drugs. FDA publishes this list as part of the ``Approved
Drug Products With Therapeutic Equivalence Evaluations,'' which is
generally known as the ``Orange Book.'' Under FDA regulations, a drug
is removed from the list if the Agency withdraws or suspends approval
of the drug's NDA or ANDA for reasons of safety or effectiveness, or if
FDA determines that the listed drug was withdrawn from sale for reasons
of safety or effectiveness (21 CFR 314.162).
    Under Sec.  314.161(a) (21 CFR 314.161(a)), the Agency must
determine whether a listed drug was withdrawn from sale for reasons of
safety or effectiveness: (1) before an ANDA that refers to that listed
drug may be approved, (2) whenever a listed drug is voluntarily
withdrawn from sale and ANDAs that refer to the listed drug have been
approved, and (3) when a person petitions for such a determination
under 21 CFR 10.25(a) and 10.30. Section 314.161(d) provides that if
FDA determines that a listed drug was withdrawn from sale for safety or
effectiveness reasons, the Agency will initiate proceedings that could
result in the withdrawal of approval of the ANDAs that refer to the
listed drug.
    FDA has become aware that the drug products listed in the table are
no longer being marketed.

----------------------------------------------------------------------------------------------------------------
                                             Active
  Application No.       Drug name        ingredient(s)       Strength(s)     Dosage form/route      Applicant
----------------------------------------------------------------------------------------------------------------
NDA 006530........  AVC..............  Sulfanilamide....  15%..............  Cream; Vaginal...  Mylan Specialty
                                                                                LP.
NDA 007936........  SELSUN...........  Selenium Sulfide.  2.5%.............  Lotion/Shampoo;    Chattem, Inc.
                                                                              Topical.
NDA 008816........  XYLOCAINE........  Lidocaine          2%...............  Jelly; Topical...  Akorn.
                                        Hydrochloride.
NDA 009218........  COUMADIN.........  Warfarin Sodium..  1 Milligram (mg).  Tablet; Oral.....  Bristol Myers
                                                                                Squibb.
NDA 012806........  CORDRAN SP.......  Flurandrenolide..  0.025%...........  Cream; Topical...  Almirall.
NDA 016647........  QUINAGLUTE.......  Quinidine          324 mg...........  Tablet, Extended   Bayer
                                        Gluconate.                            Release; Oral.     Healthcare.
NDA 017386........  ZAROXOLYN........  Metolazone.......  2.5 mg; 5 mg; 10   Tablet; Oral.....  Lannett Co.,
                                                           mg.                                   Inc.
NDA 017531........  TIGAN............  Trimethobenzamide  300 mg...........  Capsule; Oral....  King Pharms LLC.
                                        Hydrochloride.
NDA 018081........  DEPAKENE.........  Valproic Acid....  250 mg...........  Capsule; Oral....  AbbVie Inc.
NDA 018281........  TEGRETOL.........  Carbamazepine....  100 mg...........  Tablet, Chewable;  Novartis.
                                                                              Oral.
NDA 018303........  LOPRESSOR HCT....  Hydrochlorothiazi  25mg; 100mg......  Tablet; Oral.....  Validus Pharms.
                                        de; Metoprolol
                                        Tartrate.
NDA 018878........  INDOCIN..........  Indomethacin       EQ 1 mg Base/Vial  Injectable;        Recordati Rare
                                        Sodium.                               Injection.         Diseases.
NDA 019404........  OCUFEN...........  Flurbiprofen       0.03%............  Solution/Drops;    Allergan.
                                        Sodium.                               Ophthalmic.
NDA 019661........  CYTOVENE.........  Ganciclovir        EQ 500 mg Base/    Injectable;        Cheplapharm.
                                        Sodium.            Vial.              Injection.
NDA 019697........  ORTHO TRI-CYCLEN.  Ethinyl            0.035 mg, 0.035    Tablet; Oral.....  Janssen Pharms.
                                        Estradiol;         mg, 0.035 mg;
                                        Norgestimate.      0.18 mg, 0.215
                                                           mg, 0.25 mg.
NDA 019766........  ZOCOR............  Simvastatin......  80 mg............  Tablet; Oral.....  Organon.
NDA 019814........  BETAGAN..........  Levobunolol        0.25%............  Solution/Drops;    Allergan.
                                        Hydrochloride.                        Ophthalmic.
NDA 019856........  SINEMET CR.......  Carbidopa;         25 mg, 100 mg; 50  Tablet, Extended   Organon.
                                        Levodopa.          mg, 200 mg.        Release; Oral.
NDA 019907........  OPTIPRANOLOL.....  Metipranolol       0.3%.............  Solution/Drops;    Bausch and Lomb.
                                        Hydrochloride.                        Ophthalmic.
NDA 019968........  ULTRAVATE........  Halobetasol        0.05%............  Ointment; Topical  Sun Pharm Inds.
                                        Propionate.                                              Inc.
NDA 020010........  LOTRISONE........  Betamethasone      EQ 0.05% Base; 1%  Lotion; Topical..  Merck Sharp
                                        Dipropionate;                                            Dohme.
                                        Clotrimazole.
NDA 020381........  NIASPAN..........  Niacin...........  500 mg; 750 mg;    Tablet, Extended   AbbVie Inc.
                                                           1g.                Release; Oral.
NDA 020412........  ZERIT............  Stavudine........  15 mg; 20 mg; 30   Capsule; Oral....  Bristol Myers
                                                           mg; 40 mg.                            Squibb.
NDA 020509........  GEMZAR...........  Gemcitabine        EQ 200 mg Base/    Injectable;        Lilly.
                                        Hydrochloride.     Vial; 1 Gram (g)   Injection.
                                                           Base/Vial.
NDA 020593........  DEPACON..........  Valproate Sodium.  100 mg Base/       Injectable;        AbbVie Inc.
                                                           Milliliter (mL).   Injection.
NDA 020615........  DURACLON.........  Clonidine          5 mg/10 mL (0.5    Injectable;        Mylan
                                        Hydrochloride.     mg/mL).            Injection.         Institutional.
NDA 020718........  INTEGRILIN.......  Eptifibatide.....  2 mg/mL; 75 mg/    Injectable;        Merck Sharp
                                                           100 mL.            Injection.         Dohme.
NDA 021005........  SOLARAZE.........  Diclofenac Sodium  3%...............  Gel; Topical.....  Fougera Pharms.
NDA 021085........  AVELOX...........  Moxifloxacin       EQ 400 mg Base...  Tablet; Oral.....  Bayer
                                        Hydrochloride.                                           Healthcare.
NDA 021183........  VIDEX EC.........  Didanosine.......  125 mg; 200 mg;    Capsule, Delayed   Bristol Myers
                                                           250 mg; 400 mg.    Release Pellets;   Squibb.
                                                                              Oral.
NDA 021241........  ORTHO TRI-CYCLEN   Ethinyl            0.025 mg, 0.025    Tablet; Oral-28..  Janssen Pharms.
                     LO.                Estradiol;         mg, 0.025 mg;
                                        Norgestimate.      0.18 mg, 0.215
                                                           mg, 0.25 mg.
NDA 021300........  CLARINEX.........  Desloratadine....  0.5 mg/mL........  Solution; Oral...  Merck Sharp
                                                                                Dohme.
NDA 021312........  CLARINEX.........  Desloratadine....  2.5 mg; 5 mg.....  Tablet, Orally     Organon.
                                                                              Disintegrating;
                                                                              Oral.
NDA 021372........  ALOXI............  Palonosetron       EQ 0.25 mg Base/5  Injectable;        Helsinn
                                        Hydrochloride.     mL (EQ 0.05 mg     Intravenous.       Healthcare.
                                                           Base/mL); EQ
                                                           0.075 mg Base/
                                                           1.5 mL (EQ 0.05
                                                           mg Base/mL).
NDA 021444........  RISPERDAL........  Risperidone......  0.5 mg; 1 mg; 2    Tablet, Orally     Janssen Pharms.
                                                           mg; 3 mg; 4 mg.    Disintegrating;
                                                                              Oral.
NDA 021455........  BONIVA...........  Ibandronate        EQ 150 mg Base...  Tablet; Oral.....  Hoffmann La
                                        Sodium.                                                  Roche.
NDA 021605........  CLARINEX D 24      Desloratadine;     5 mg; 240 mg.....  Tablet, Extended   Organon.
                     HOUR.              Pseudoephedrine                       Release; Oral.
                                        Sulfate.
NDA 021858........  BONIVA...........  Ibandronate        EQ 3 mg Base/3 mL  Injectable;        Hoffmann La
                                        Sodium.                               Intravenous.       Roche.
NDA 021860........  SARAFEM..........  Fluoxetine         EQ 10 mg Base; EQ  Tablet; Oral.....  Allergan.
                                        Hydrochloride.     20 mg Base.
NDA 021956........  DUTOPROL.........  Hydrochlorothiazi  12.5 mg; EQ 25 mg  Tablet, Extended   Concordia.
                                        de; Metoprolol     Tartrate; 12.5     Release; Oral.
                                        Succinate.         mg: EQ 50 mg
                                                           Tartrate; 12.5
                                                           mg; EQ 100 mg
                                                           Tartrate.
NDA 022064........  XYZAL............  Levocetirizine     5 mg.............  Tablet; Oral.....  Chattem Sanofi.
                                        Dihydrochloride.
NDA 022106........  DORIBAX..........  Doripenem........  250 mg/Vial; 500   Injectable;        Shionogi, Inc.
                                                           mg/Vial.           Intravenous
                                                                              Infusion.
NDA 022129........  ULESFIA..........  Benzyl Alcohol...  5%...............  Lotion; Topical..  Shionogi, Inc.
NDA 022157........  XYZAL............  Levocetirizine     2.5 mg/5 mL......  Solution; Oral...  Chattem Sanofi.
                                        Dihydrochloride.
NDA 022321........  EMBEDA...........  Morphine Sulfate;  20 mg, 0.8 mg; 30  Capsule, Extended  Alpharma Pharms.
                                        Naltrexone         mg, 1.2 mg; 50     Release; Oral.
                                        Hydrochloride.     mg, 2 mg; 60 mg,
                                                           2.4 mg; 80 mg,
                                                           3.2 mg; 100 mg,
                                                           4 mg.
NDA 050261........  DECLOMYCIN.......  Demeclocycline     75 mg; 150 mg;     Tablet; Oral.....  Corepharma.
                                        Hydrochloride.     300 mg.
NDA 050405........  KEFLEX...........  Cephalexin.......  EQ 250 mg Base;    Capsule; Oral....  Pragma.
                                                           EQ 500 mg Base;
                                                           EQ 750 mg Base.
NDA 050529........  PEDIAZOLE........  Erythromycin       EQ 200 mg Base/5   Granule; Oral....  Ross Labs.
                                        Ethylsuccinate;    mL; EQ 600 mg
                                        Sulfisoxazole      Base/5 mL.
                                        Acetyl.

ANDA 083082.......  CHLOROQUINE        Chloroquine        250 mg; 500 mg...  Tablet; Oral.....  Hikma Pharms.
                     PHOSPHATE.         Phosphate.
NDA 204592........  ZORVOLEX.........  Diclofenac.......  18 mg............  Capsule; Oral....  Zyla.
----------------------------------------------------------------------------------------------------------------

    FDA has reviewed its records and, under Sec.  314.161, has
determined that the drug products listed were not withdrawn from sale
for reasons of safety or effectiveness. Accordingly, the Agency will
continue to list the drug products in the ``Discontinued Drug Product
List'' section of the Orange Book. The ``Discontinued Drug Product
List'' identifies, among other items, drug products that have been
discontinued from marketing for reasons other than safety or
effectiveness.
    Approved ANDAs that refer to the drug products listed are
unaffected by the discontinued marketing of the products subject to
these applications. Additional ANDAs that refer to these products may
also be approved by the Agency if they comply with relevant legal and
regulatory requirements. If FDA determines that labeling for these drug
products should be revised to meet current standards, the Agency will
advise ANDA applicants to submit such labeling.

    Dated: August 2, 2022.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2022-17056 Filed 8-8-22; 8:45 am]
BILLING CODE 4164-01-P


[Federal Register: October 26, 2011 (Volume 76, Number 207)]
[Notices]
[Page 66346]
[DOCID:fr26oc11-104]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Agency Information Collection Activities; Requests for Comments:
Clearance of Renewed Approval of Information Collection; Organization
Designation Authorization

AGENCY: Federal Aviation Administration (FAA), DOT.

ACTION: Notice and request for comments.

-----------------------------------------------------------------------

SUMMARY: In accordance with the Paperwork Reduction Act of 1995, FAA
invites public comments about our intention to request the Office of
Management and Budget (OMB) approval to renew an information
collection. The Federal Register Notice with a 60-day comment period
soliciting comments on the following collection of information was
published on August 24, 2011, vol. 76, no. 164, page 53023-53024. This
collection involves organizations applying to perform certification
functions on behalf of the FAA, including approving data and issuing
various aircraft and organization certificates.

DATES: Written comments should be submitted by November 25, 2011.

FOR FURTHER INFORMATION CONTACT: Kathy DePaepe at<PHONE_NUMBER>, or by
e-mail at: Kathy A. DePaepe @faa.gov.

SUPPLEMENTARY INFORMATION:
    OMB Control Number: 2120-0704.
    Title: Organization Designation Authorization.
    Form Numbers: FAA Forms 8100-11, 8100-12, 8100-13.
    Type of Review: Renewal of an information collection.
    Background: Subpart D to part 183 allows the FAA to appoint
organizations as representatives of the administrator. As authorized,
these organizations perform certification functions on behalf of the
FAA. Applications are submitted to the appropriate FAA office and are
reviewed by the FAA to determine whether the applicant meets the
requirements necessary to be authorized as a representative of the
Administrator. Procedures manuals are submitted and approved by the FAA
as a means to ensure that the correct processes are utilized when
performing functions on behalf of the FAA. These requirements are
necessary to manage the various approvals issued by the organization
and to document approvals issued and must be maintained in order to
address potential future safety issues.
    Respondents: Approximately 83 applicants.
    Frequency: Information is collected on occasion.
    Estimated Average Burden per Response: 41.7 hours.
    Estimated Total Annual Burden: 5,158 hours.

ADDRESSES: Interested persons are invited to submit written comments on
the proposed information collection to the Office of Information and
Regulatory Affairs, Office of Management and Budget. Comments should be
addressed to the attention of the Desk Officer, Department of
Transportation/FAA, and sent via electronic mail to oira_
<EMAIL_ADDRESS>or faxed to<PHONE_NUMBER>, or mailed to the
Office of Information and Regulatory Affairs, Office of Management and
Budget, Docket Library, Room 10102, 725 17th Street, NW., Washington,
DC 20503.
    Public Comments Invited: You are asked to comment on any aspect of
this information collection, including (a) Whether the proposed
collection of information is necessary for FAA's performance; (b) the
accuracy of the estimated burden; (c) ways for FAA to enhance the
quality, utility and clarity of the information collection; and (d)
ways that the burden could be minimized without reducing the quality of
the collected information. The agency will summarize and/or include
your comments in the request for OMB's clearance of this information
collection.

    Issued in Washington, DC, on October 20, 2011.
Albert R. Spence,
FAA Assistant Information Collection Clearance Officer, IT Enterprises
Business Services Division, AES-200.
[FR Doc. 2011-27712 Filed 10-25-11; 8:45 am]
BILLING CODE 4910-13-P


[Federal Register Volume 86, Number 97 (Friday, May 21, 2021)]
[Rules and Regulations]
[Pages 27518-27519]
[FR Doc No: 2021-10738]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HOMELAND SECURITY

Coast Guard

33 CFR Part 100

[Docket No. USCG-2021-0255]

Special Local Regulations; Great Western Tube Float, Parker, AZ

AGENCY: Coast Guard, DHS.

ACTION: Notice of enforcement of regulation.

-----------------------------------------------------------------------

SUMMARY: The Coast Guard will enforce the special local regulation for
the Great Western Tube Float on June 12, 2021. These special local
regulations are necessary to provide for the safety of the
participants, crew, spectators, sponsor vessels, and general users of
the waterway. Our regulation for marine events within the Eleventh
Coast Guard District identifies the regulated area for this event in
Parker, AZ. During the enforcement period, persons and vessels are
prohibited from anchoring, blocking, loitering, or impeding within this
regulated area unless authorized by the Captain of the Port, or his
designated representative.

DATES: The regulations in 33 CFR 100.1102 Table 1, Item 9 will be
enforced from 7 a.m. to 6 p.m. on June 12, 2021.

FOR FURTHER INFORMATION CONTACT: If you have questions about this
notice of enforcement, call or email Lieutenant John Santorum,
Waterways Management, U.S. Coast Guard Sector San Diego, CA; telephone
619-278-7656, email<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION: The Coast Guard will enforce the special
local regulations in 33 CFR 100.1102 Table 1, Item 9 of that section
for the Great Western Tube Float in Parker, AZ from 7 a.m. to 6 p.m. on
June 12, 2021. This

enforcement action is being taken to provide for the safety of life on
navigable waterways during the event. Our regulation for marine events
within the Eleventh Coast Guard District, Sec.  100.1102, specifies the
location of the regulated area for the Great Western Tube Float which
encompasses the navigable waters of the Colorado River from Buckskin
Mountain State Park to La Paz County Park. Under the provisions of
Sec.  100.1102, persons and vessels are prohibited from anchoring,
blocking, loitering, or impeding within this regulated area, unless
authorized by the Captain of the Port, or his designated
representative. The Coast Guard may be assisted by other Federal,
State, or local law enforcement agencies in enforcing this regulation.
    In addition to this notice of enforcement in the Federal Register,
the Coast Guard plans to provide notification of this enforcement
period via the Local Notice to Mariners and local advertising by the
event sponsor.
    If the Captain of the Port Sector San Diego or his designated
representative determines that the regulated area need not be enforced
for the full duration stated on this document, he or she may use a
Broadcast Notice to Mariners or other communications coordinated with
the event sponsor to grant general permission to enter the regulated
area.

    Dated: May 14, 2021.
T.J. Barelli,
Captain, U.S. Coast Guard, Captain of the Port San Diego.
[FR Doc. 2021-10738 Filed 5-20-21; 8:45 am]
BILLING CODE 9110-04-P


[Federal Register: February 19, 2009 (Volume 74, Number 32)]
[Notices]
[Page 7714-7715]
[DOCID:fr19fe09-83]

-----------------------------------------------------------------------

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34-59388; File No. SR-DTC-2009-02]

Self-Regulatory Organizations; The Depository Trust Company;
Notice of Filing of Proposed Rule Change To Implement a Maturity
Presentment Pend Function To Replace the Maturity Presentment
Contingency System

February 11, 2009.
    Pursuant to Section 19(b)(1) of the Securities Exchange Act of 1934
(``Act'') \1\ and Rule 19b-4 thereunder \2\ notice is hereby given that
on January 13, 2009, The Depository Trust Company (``DTC'') filed with
the Securities and Exchange Commission (``Commission'') the proposed
rule change described in Items I, II, and III below, which items have
been prepared primarily by DTC. The Commission is publishing this
notice to solicit comments on the proposed rule change from interested
parties.
---------------------------------------------------------------------------

    \1\ 15 U.S.C. 78s(b)(1).
    \2\ 17 CFR 240.19b-4.
---------------------------------------------------------------------------

I. Self-Regulatory Organization's Statement of the Terms of Substance
of the Proposed Rule Change

    The proposed rule change seeks to implement a Maturity Presentment
Pend function (``IPA MP Pend Function'') that will replace the Maturity
Presentment Contingency System.

II. Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

    In its filing with the Commission, DTC included statements
concerning the purpose of and basis for the proposed rule change and
discussed any comments it received on the proposed rule change. The
text of these statements may be examined at the places specified in
Item IV below. DTC has prepared summaries, set forth in sections (A),
(B), and (C) below, of the most significant aspects of these
statements.\3\
---------------------------------------------------------------------------

    \3\ The Commission has modified the text of the summaries
prepared by DTC.
---------------------------------------------------------------------------

(A) Self-Regulatory Organization's Statement of the Purpose of, and
Statutory Basis for, the Proposed Rule Change

Current MMI Maturity Payment Procedure
    Currently, as part of DTC's Money Market Instrument (``MMI'')
program maturity payment procedures, DTC sweeps maturing MMI positions
from investors' custodians accounts and generates Maturity Presentments
(``MPs'') \4\ to the designated Issuing Agent or Paying Agent's
(collectively, ``IPA'') accounts. DTC debits the IPA's account by the
amount of the maturity proceeds for settlement that day and credits the
same amount to the investor's custodian account for payment that day.
Because MPs are processed against an IPA's DTC account, IPAs may refuse
to pay for a specific issuer's MP in the event that the issuer defaults
on its obligation to the IPA. DTC allows IPAs to enter refusal to pay
notifications through the Participant Terminal System (``PTS'') until 3
p.m. Eastern Time on the date of maturity.\5\
---------------------------------------------------------------------------

    \4\ References to MPs also cover other payment obligations of
MMI issuers such as periodic payments and periodic interest
payments.
    \5\ If the IPA refuses to pay, then DTC follows its Defaulting
Issuer procedures, which include devaluing the collateral value of
all of the defaulting issuer's MMI to zero, reversing all of the
issuer's issuances and maturities processed that day, notifying DTC
participants of the default, and blocking all further issuances by
the issuer from entering DTC. If an IPA then contacts DTC to reverse
the refusal to pay instruction, DTC undoes all the actions it took
under its Defaulting Issuer procedures.
---------------------------------------------------------------------------

    Under extraordinary circumstances or in times of unusual market
stress, DTC may use the Maturity Presentment Contingency System
(``MPCS'') on the days following a disaster and after consultation with
the Commission to allow IPA banks to review and manually release MPs.
IPAs are able to release MPs for processing on a CUSIP or issuer
acronym level basis. At the close of settlement, MPs that have not been
released are rolled into the next business day's processing queue for
representation along with that day's scheduled obligations. This
process continues until all maturities are funded and the IPA releases
the MP, the IPA notifies DTC of its refusal to pay, or the MPCS
contingency procedure is terminated.

Proposed MMI Maturity Payment Procedure
    DTC is proposing to enhance its systems in order to provide IPAs
the ability to monitor their credit exposure to MMI issuers. DTC's
proposed IPA MP Pend Function will enable IPAs to review and manually
release MPs in the ordinary course of business. IPAs will have the
ability to set the pend request anytime prior to the MP sweep or at any
point during the day for unknown rate maturities, based on acronym,
product type, or the issuer MMI base CUSIP number. Each day, DTC will
require the IPA to (1) release all items held in pend or (2) invoke its
right to refuse to pay.\6\ If the IPA takes no action by 3 p.m. Eastern
Time, the pending items will be released by DTC for normal processing.
---------------------------------------------------------------------------

    \6\ The IPA MP Pend Function differs from the MPCS in this
regard. Under the MPCS system, IPAs are not required to release
items held in pend or invoke their right to refuse to pay each day
since the MPs are rolled over into the next business day's
processing queue.
---------------------------------------------------------------------------

    All MP Pend requests will be time-stamped and will be immediately
effective. Participants with MMI positions will be able to ascertain
which MPs have been placed in pend status by the IPA.
    Each time it uses the IPA MP Pend Function to create a pend request
or make a change to its profile, the IPA will be required to represent
and warrant that it has authority to submit the request appearing on
the IPA's screen and that it will either release the items held in pend
by 3 p.m. Eastern Time on the date of maturity or by such time
communicate to DTC that it refuses to pay. Additionally, the IPA must
acknowledge that it understands and agrees that all MPs will be
released for normal processing if it does not communicate its intention
to refuse to pay DTC by 3 p.m. Eastern Time. In extraordinary
circumstances, DTC will maintain its ability to set the pend request
based on an issuer acronym, product, program, base number, or globally
for all IPAs or for individual IPAs. In all circumstances, the IPA will
maintain its right to notify DTC of its refusal to pay.
    DTC believes that the proposed rule change is consistent with the
requirements of Section 17A of the Act \7\ and the rules and
regulations thereunder because the proposed change will reduce the
amount of late day reversals associated with an IPA's refusal to pay
notification at 3 p.m. thereby reducing the operational and financial
risks associated with reversals of refusals to pay and promoting the
prompt and accurate settlement of securities transactions.
---------------------------------------------------------------------------

    \7\ 15 U.S.C. 78q-1.
---------------------------------------------------------------------------

(B) Self-Regulatory Organization's Statement on Burden on Competition

    DTC does not believe that the proposed rule change will have any
impact or impose any burden on competition.

(C) Self-Regulatory Organization's Statement on Comments on the
Proposed Rule Change Received From Members, Participants, or Others

    The proposal was developed in consultation with various industry
organizations. Written comments relating to the proposed rule change
have not been solicited or received. DTC will notify the Commission of
any written comments received by DTC.

III. Date of Effectiveness of the Proposed Rule Change and Timing for
Commission Action

    Within thirty-five days of the date of publication of this notice
in the Federal Register or within such longer period: (i) As the
Commission may designate up to ninety days of such date if it finds
such longer period to be appropriate and publishes its reasons for so
finding or (ii) as to which the self-regulatory organization consents,
the Commission will:
    (A) By order approve such proposed rule change or
    (B) Institute proceedings to determine whether the proposed rule
change should be disapproved.

IV. Solicitation of Comments

    Interested persons are invited to submit written data, views, and
arguments concerning the foregoing, including whether the proposed rule
change is consistent with the Act. Comments may be submitted by any of
the following methods:

Electronic Comments

     Use the Commission's Internet comment form (http://
www.sec.gov/rules/sro.shtml) or
     Send an e-mail to<EMAIL_ADDRESS>Please include
File Number SR-DTC-2009-02 on the subject line.

Paper Comments

     Send paper comments in triplicate to Elizabeth M. Murphy,
Secretary, Securities and Exchange Commission, 100 F Street, NE.,
Washington, DC 20549-1090.

All submissions should refer to File Number SR-DTC-2009-02. This file
number should be included on the subject line if e-mail is used. To
help the Commission process and review your comments more efficiently,
please use only one method. The Commission will post all comments on
the Commission's Internet Web site (http://www.sec.gov/rules/
sro.shtml). Copies of the submission, all subsequent amendments, all
written statements with respect to the proposed rule change that are
filed with the Commission, and all written communications relating to
the proposed rule change between the Commission and any person, other
than those that may be withheld from the public in accordance with the
provisions of 5 U.S.C. 552, will be available for inspection and
copying in the Commission's Public Reference Section, 100 F Street,
NE., Washington, DC 20549, on official business days between the hours
of 10 a.m. and 3 p.m. Copies of such filings also will be available for
inspection and copying at the principal office of DTC and on DTC's Web
site at http://www.dtcc.com/downloads/legal/rule_filings/2009/dtc/
2009-02.pdf. All comments received will be posted without change; the
Commission does not edit personal identifying information from
submissions. You should submit only information that you wish to make
available publicly. All submissions should refer to File Number SR-DTC-
2009-02 and should be submitted on or before March 12, 2009.
---------------------------------------------------------------------------

    \8\ 17 CFR 200.30-3(a)(12).

    For the Commission by the Division of Trading and Markets,
pursuant to delegated authority.\8\
Florence E. Harmon,
Deputy Secretary.
[FR Doc. E9-3425 Filed 2-18-09; 8:45 am]

BILLING CODE 8011-01-P


Table II 2 FAA Terminal Area Forecast Summary Report of Nationwide Air Carrier Operations a, b, c, d a Source: U. S. FAA, " APO Terminal Area Forecast Summary Report, " Aircraft Operations, December 14, 2000; and " APO Terminal Area Forecast Summary Report  Forecast Pending publication February, 2005."

bOperations means the number of arrivals and departures ( www. apo. data. faa. gov/ gloss. html).

cAir Carrier Operations refers to commercial aircraft with seating capacity of more than 60 seats.

d Commuter / Air Taxi refers to aircraft with 60 or fewer seats conducting scheduled commercial flights / non scheduled or for higher flights.

e The change in operations from 2001 to 2002 was + 4.1 % for the 12/ 14/ 2000 forecast, and it was  6.5% for the 2/ 2005 forecast.

Note: ( not intended for publication in draft NPRM) EPA only showed Air Carrier Operations (> 60 seats) in the draft NPRM, however,

Commuter / Air Taxi represents a large part of the commercial market. In the vinal version of the NPRM, Combine the two into one to indicate " Commercial Aircraft."

2/ 14/ 2000 Data indicate 32.7% growth from the year 2000 to the year 2015.

2/ 01/ 2004 Data indicate 24.0% growth from the year 2000 to the year 2015.

12/ 14/ 2000 Forecast ( pre 9/ 11) 3/ 01/ 2004 Forecast ( post 9/ 11) % Change Year Air Carrier Operations Commuter /

Air Taxi Total % Change between years listed Air Carrier Operations Commuter/

Air Taxi Total % Change between years listed Versus Original Forecast 1999 15,127,419 13,733,312 28,860,731 14,769,055 14,178,445 28,947,500 0.3%

2000 15,476,135 13,969,484 29,445,619 2.0% 15,239,632 14,475,363 29,714,995 2.7% 0.9%

2001 15,819,505 14,214,462 30,033,967 2.0% 14,806,610 14,559,611 29,366,221  1.2%  2.2%

2002 16,210,777 14,452,731 30,663,508 2.1% 13,748,561 14,055,409 27,803,970  5.3%  9.3%

2005 17,445,705 15,173,489 32,619,194 6.4% 13,299,330 16,586,847 29,886,177 7.5%  8.4%

2010 19,664,128 16,351,467 36,015,595 10.4% 14,992,953 18,129,131 33,122,084 10.8%  8.0%

2015 22,004,067 17,545,459 39,549,526 9.8% 16,671,353 19,608,451 36,279,804 9.5%  8.3%

2020 N/ A 18,475,063 21,216,393 39,691,456 9.4% Current Forecast is 73%, or about 3/ 4 of the 2000 forecast.


[Federal Register: February 3, 2010 (Volume 75, Number 22)]
[Notices]
[Page 5582-5583]
[DOCID:fr03fe10-38]

-----------------------------------------------------------------------

ENVIRONMENTAL PROTECTION AGENCY

[EPA-HQ-OPP-2005-0123; FRL-8805-9]

Methyl Bromide; Amendments to Terminate Uses

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This notice announces EPA's order for the amendments to
terminate uses, voluntarily requested by the registrants and accepted
by the Agency, of products containing the pesticide methyl bromide
listed in Table 1, pursuant to section 6(f)(1) of the Federal
Insecticide, Fungicide, and Rodenticide Act (FIFRA), as amended. This
order follows a September 30, 2009 Federal Register Notice of Receipt
of Requests from the registrants listed in Table 2 to amend to
terminate post-harvest methyl bromide uses in or on alfalfa hay and
cottonseed for these product registrations. These are the last products
containing the pesticide methyl bromide registered for use on alfalfa
hay and cotton seed in the United States. In the September 30, 2009
notice, EPA indicated that it would issue an order implementing the
amendments to terminate uses, unless the Agency received substantive
comments within the 30-day comment period that would merit its further
review of these requests, or unless the registrants withdrew their
requests within this period. The Agency did not receive any comments on
the notice. Further, the registrants did not withdraw their requests.
Accordingly, EPA hereby issues in this notice a cancellation order
granting the requested amendments to terminate uses. Any distribution,
sale, or use of the products subject to this cancellation order is
permitted only in accordance with the terms of this order,

including any existing stocks provisions.

DATES: The cancellations are effective February 3, 2010.

FOR FURTHER INFORMATION CONTACT:  Susan Bartow, Pesticide Re-evaluation
Division (7508P), Office of Pesticide Programs, Environmental
Protection Agency, 1200 Pennsylvania Ave., NW., Washington, DC 20460-
0001; telephone number:<PHONE_NUMBER>; fax number:<PHONE_NUMBER>; e-
mail address<EMAIL_ADDRESS>
SUPPLEMENTARY INFORMATION:

I. General Information

A. Does this Action Apply to Me?

     This action is directed to the public in general, and may be of
interest to a wide range of stakeholders including environmental, human
health, and agricultural advocates; the chemical industry; pesticide
users; and members of the public interested in the sale, distribution,
or use of pesticides. Since others also may be interested, the Agency
has not attempted to describe all the specific entities that may be
affected by this action. If you have any questions regarding the
applicability of this action to a particular entity, consult the person
listed under FOR FURTHER INFORMATION CONTACT.

B. How Can I Get Copies of this Document and Other Related Information?

    EPA has established a docket for this action under docket
identification (ID) number EPA-HQ-OPP-2005-0123. Publicly available
docket materials are available either in the electronic docket at
http://www.regulations.gov, or, if only available in hard copy, at the
Office of Pesticide Programs (OPP) Regulatory Public Docket in Rm. S-
4400, One Potomac Yard (South Bldg.), 2777 S. Crystal Dr., Arlington,
VA. The hours of operation of this Docket Facility are from 8:30 a.m.
to 4 p.m., Monday through Friday, excluding legal holidays. The Docket
Facility telephone number is<PHONE_NUMBER>.

II. What Action is the Agency Taking?

    This notice announces the amendments to terminate uses, as
requested by registrants, of products registered under section 3 of
FIFRA. These registrations are listed in ascending order by
registration number in Table 1 of this unit.

  Table 1.--Methyl Bromide Product Registration Amendments to Terminate
                                  Uses
------------------------------------------------------------------------
          EPA Registration Number                   Product Name
------------------------------------------------------------------------
5785-11                                     Meth-O-Gas 100
------------------------------------------------------------------------
5785-41                                     Meth-O-Gas Q
------------------------------------------------------------------------
8536-15                                     Methyl Bromide 100
------------------------------------------------------------------------
8536-29                                     Methyl Bromide Quarantine
                                             Fumigant
------------------------------------------------------------------------
8622-16                                     Metabrom 100
------------------------------------------------------------------------
8622-55                                     Metabrom Q
------------------------------------------------------------------------

    Table 2 of this unit includes the names and addresses of record for
all registrants of the products in Table 1 of this unit, in ascending
order by EPA company number.

                Table 2.--Registrants of Amended Products
------------------------------------------------------------------------
            EPA Company Number                Company Name and Address
------------------------------------------------------------------------
5785                                        Great Lakes Chemical
                                             Corporation
                                            P.O. Box 2200
                                            West Lafayette, IN 47996-
                                             2200
------------------------------------------------------------------------
8536                                        Soil Chemicals Corporation
                                             (doing business as Cardinal
                                             Professional Products)
                                            P.O. Box 782
                                            Hollister, CA 95024-9487
------------------------------------------------------------------------
8622                                        ICL-IP America, Inc.
                                            95 MacCorkle Avenue, S.W.
                                            South Charleston, WV 25303-
                                             1411
------------------------------------------------------------------------

III. Summary of Public Comments Received and Agency Response to
Comments

    During the public comment period provided, EPA received no comments
in response to the September 30, 2009 Federal Register notice
announcing the Agency's receipt of the requests for amendments to
terminate uses of products listed in Table 1.

IV. Cancellation Order

    Pursuant to FIFRA section 6(f), EPA hereby approves the requested
amendments to terminate uses of methyl bromide registrations identified
in Table 1 of Unit II. Accordingly, the Agency orders that the product
registrations identified in Table 1 of Unit II. are hereby amended to
terminate the affected uses. Any distribution, sale, or use of existing
stocks of the products identified in Table 1 of Unit II. in a manner
inconsistent with any of the Provisions for Disposition of Existing
Stocks set forth in Unit VI. will be considered a violation of FIFRA.

V. What is the Agency's Authority for Taking this Action?

    Section 6(f)(1) of FIFRA provides that a registrant of a pesticide
product may at any time request that any of its pesticide registrations
be canceled or amended to terminate one or more uses. FIFRA further
provides that, before acting on the request, EPA must publish a notice
of receipt of any such request in the Federal Register. Thereafter,
following the public comment period, the Administrator may approve such
a request.

VI. Provisions for Disposition of Existing Stocks

    The registrants requested the following provisions for sale,
distribution, and use of existing stocks and the Agency approves the
requested provisions for sale, distribution, and use of existing
stocks:
    1. All sale or distribution by the registrant of existing stocks
labeled for post-harvest alfalfa hay and post-harvest cottonseed uses
is prohibited after October 31, 2009, unless that sale or distribution
is solely for the purpose of facilitating disposal or export of the
product.
    2. Existing stocks labeled for post-harvest alfalfa hay and post-
harvest cottonseed uses may be sold and distributed by persons other
than the registrant until October 31, 2010.
    3. Existing stocks labeled for post-harvest alfalfa hay and post-
harvest cottonseed uses may be used until all such stocks are
exhausted, provided that such use complies with the EPA-approved label
of the product.

List of Subjects

    Environmental protection, Pesticides and pests.

    Dated: January 19, 2010.
Richard P. Keigwin, Jr.,
Director, Pesticide Re-evaluation Division, Office of Pesticide
Programs.
[FR Doc. 2010-1991 Filed 2-2-10; 8:45 am]
BILLING CODE 6560-50-S


[Federal Register Volume 81, Number 92 (Thursday, May 12, 2016)]
[Notices]
[Pages 29617-29618]
[FR Doc No: 2016-10937]

-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Pipeline and Hazardous Materials Safety Administration

Hazardous Materials: Delayed Applications

AGENCY: Office of Hazardous Materials Safety, Pipeline and Hazardous
Materials Safety Administration (PHMSA), DOT.

ACTION: List of application delayed more than 180 days.

-----------------------------------------------------------------------

SUMMARY: In accordance with the requirements of 49 U.S.C. 5117(c),
PHMSA is publishing the following list of special permit applications
that have been in process for 180 days or more. The reason(s) for delay
and the expected completion date for action on each application is
provided in association with each identified application.

FOR FURTHER INFORMATION CONTACT: Ryan Paquet, Director, Office of
Hazardous Materials Special Permits and Approvals, Pipeline and
Hazardous Materials Safety Administration, U.S. Department of
Transportation, East Building, PHH-30, 1200 New Jersey Avenue
Southeast, Washington, DC 20590-0001,<PHONE_NUMBER>

SUPPLEMENTARY INFORMATION:

Key to ``Reason for Delay''

1. Awaiting additional information from applicant
2. Extensive public comment under review
3. Application is technically complex and is of significant impact
or precedent-setting and requires extensive analysis
4. Staff review delayed by other priority issues or volume of
special permit applications

Meaning of Application Number Suffixes

N--New application
M--Modification request
R--Renewal Request
P--Party To Exemption Request

    Issued in Washington, DC, on April 27, 2016.
Donald Burger,
Chief, General Approvals and Permits.

----------------------------------------------------------------------------------------------------------------
                                                                  Reason for
         Application No.                    Applicant                delay        Estimated date of completion
----------------------------------------------------------------------------------------------------------------
                                         Modification to Special Permits
----------------------------------------------------------------------------------------------------------------
16412-M..........................   Nantong CIMC Tank                        4  05-31-2016
                                    Equipment Co. Ltd.,
                                    Jiangsu, Province.
16035-M..........................   LCF Systems, Inc.,                       4  05-31-2016
                                    Scottsdale, AZ.
14778-M..........................  Metalcraft/Sea-Fire Marine,               4  05-31-2016
                                    Baltimore, MD.
15610-M..........................  TechKnowServ Corp., State                 4  05-31-2016
                                    College, PA.
15537-M..........................   Alaska Pacific Powder                    4  05-31-2016
                                    Company, Watkins, CO.
7607-M...........................  Thermo Fisher Scientific,                 4  05-31-2016
                                    Franklin, MA.
----------------------------------------------------------------------------------------------------------------
                                         New Special Permit Applications
----------------------------------------------------------------------------------------------------------------
16495-N..........................  TransRail Innovation Inc.,                4  05-31-2016
                                    Calgary.
16524-N..........................  Quantum Fuel Systems                      4  05-15-2016
                                    Technologies Worldwide,
                                    Inc., Lake Forest, CA.
16463-N..........................  Salco Products, Lemont, IL.               3  05-31-2016
16559-N..........................   HTEC Hydrogen Technology &               4  05-30-2016
                                    Energy Corporation, North
                                    Vancouver, BC, Canada.
16571-N..........................   Chevron USA Inc.,                        4  05-15-2016
                                    Picayune, MS.
16560-N..........................   LightSail Energy, Inc.,                  4  05-10-2016
                                    Berkeley, CA.
15767-N..........................   Union Pacific, Railroad                  3  05-31-2016
                                    Company, Omaha, NE.
----------------------------------------------------------------------------------------------------------------

[FR Doc. 2016-10937 Filed 5-11-16; 8:45 am]
 BILLING CODE 4910-60-M


[Federal Register Volume 77, Number 129 (Thursday, July 5, 2012)]
[Notices]
[Pages 39694-39695]
[FR Doc No: 2012-16386]

-----------------------------------------------------------------------

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Combined Notice of Filings 1

    Take notice that the Commission received the following electric
rate filings:

    Docket Numbers: ER10-1894-004; ER10-1901-005; ER10-1882-001; ER10-
3025-001; ER10-3036-001; ER10-3039-001; ER10-3042-001.
    Applicants: Wisconsin Public Service Corporation, Upper Peninsula
Power Company, Integrys Energy Services, Inc., Wisconsin River Power
Company, Quest Energy, LLC, WPS Power Development, LLC, Combined Locks
Energy Center, LLC.

    Description: The Integrys Energy Group submits Updated Market
Analysis for their market based rate authority in the Central Region.
    Filed Date: 6/26/12.
    Accession Number: 20120626-5146.
    Comments Due: 5 p.m. ET 8/27/12.

    Docket Numbers: ER10-2839-001.
    Applicants: Midland Cogeneration Venture Limited Partnership.
    Description: Updated Market Power Analysis of Midland Cogeneration
Venture Limited Partnership.
    Filed Date: 6/27/12.
    Accession Number: 20120627-5061.
    Comments Due: 5 p.m. ET 8/27/12.

    Docket Numbers: ER12-1803-001.
    Applicants: Cleco Power LLC.
    Description: Compliance Filing to be effective 5/14/2012.
    Filed Date: 6/27/12.
    Accession Number: 20120627-5034.
    Comments Due: 5 p.m. ET 7/18/12.

    Docket Numbers: ER12-2071-002.
    Applicants: Verde Energy USA New York, LLC.
    Description: Revised Amended MBR Filing to be effective 8/20/2012.
    Filed Date: 6/27/12.
    Accession Number: 20120627-5029.
    Comments Due: 5 p.m. ET 7/18/12.

    Docket Numbers: ER12-2112-000.
    Applicants: ISO New England Inc.
    Description: ISO New England Inc. Informational Filing Related to
the Peak Energy Rent Feature of the Forward Capacity Market.
    Filed Date: 6/26/12.
    Accession Number: 20120626-5161.
    Comments Due: 5 p.m. ET 7/17/12.

    Docket Numbers: ER12-2113-000.
    Applicants: Hess Small Business Services LLC.
    Description: Market-Based Rate Tariff Revisions to be effective 6/
28/2012.
    Filed Date: 6/27/12.
    Accession Number: 20120627-5066.
    Comments Due: 5 p.m. ET 7/18/12.

    Docket Numbers: ER12-2114-000.
    Applicants: Carolina Power & Light Company.
    Description: Rate Schedule No. 184 of Carolina Power and Light
Company to be effective 7/1/2012.
    Filed Date: 6/27/12.
    Accession Number: 20120627-5072.
    Comments Due: 5 p.m. ET 7/18/12.

    The filings are accessible in the Commission's eLibrary system by
clicking on the links or querying the docket number.
    Any person desiring to intervene or protest in any of the above
proceedings must file in accordance with Rules 211 and 214 of the
Commission's Regulations (18 CFR 385.211 and 385.214) on or before 5
p.m. Eastern time on the specified comment date. Protests may be
considered, but intervention is necessary to become a party to the
proceeding.
    eFiling is encouraged. More detailed information relating to filing
requirements, interventions, protests, service, and qualifying
facilities filings can be found at: http://www.ferc.gov/docs-filing/efiling/filing-req.pdf. For other information, call<PHONE_NUMBER>
(toll free). For TTY, call<PHONE_NUMBER>.

    Dated: June 27, 2012.
Nathaniel J. Davis, Sr.,
Deputy Secretary.
[FR Doc. 2012-16386 Filed 7-3-12; 8:45 am]
BILLING CODE 6717-01-P


[Federal Register Volume 81, Number 172 (Tuesday, September 6, 2016)]
[Notices]
[Pages 61290-61291]
[FR Doc No: 2016-21403]

=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

Seventh Meeting of SC-233 Addressing Human Factors/Pilot
Interface Issues for Avionics

AGENCY: Federal Aviation Administration (FAA), U.S. Department of
Transportation (DOT).

ACTION: Seventh Meeting of the SC-233 addressing human factors/pilot
interface issues for avionics.

-----------------------------------------------------------------------

SUMMARY: The FAA is issuing this notice to advise the public of a
meeting of Seventh Meeting of SC-233 Addressing Human Factors/Pilot
Interface Issues for Avionics.

DATES: The meeting will be held September 27-29, 2016, 9:00 a.m. to
4:30 p.m.

ADDRESSES: The meeting will be held at: 1150 18th Street NW., Suite
910, Washington, DC 20036.

FOR FURTHER INFORMATION CONTACT: Jennifer Iversen at<EMAIL_ADDRESS>or<PHONE_NUMBER>, or The RTCA Secretariat, 1150 18th Street NW., Suite
910, Washington, DC 20036, or by telephone at<PHONE_NUMBER>, fax at
(202) 833-9434, or Web site at http://www.rtca.org.

SUPPLEMENTARY INFORMATION: Pursuant to section 10(a) (2) of the Federal
Advisory Committee Act (Pub. L. 92-463, 5 U.S.C., App.), notice is
hereby given for a meeting of the Seventh Meeting of the SC-233,
Addressing Human Factors/Pilot Interface Issues for Avionics. The
agenda will include the following:

September 27-29, 2016, 9:00 a.m. to 4:30 p.m.

Tuesday September 27, 2016

AM
     Introduction, Upcoming PMC Dates and Deliverable
     Review of TOR
     June meeting summary
     Roadmap for remaining items to be completed; notional
schedule of activities remaining
     Consensus on document review process

PM
     Overview of the combined document and initial feedback
     Detailed review of document and identification of work to
be done

Wednesday September 28, 2016
     Working Groups Break Out Sessions
     End of the Day Working Group Status Report Outs

Thursday September 29, 2016

AM
     Working Groups Break Out Session

PM
     Working Group Status
    1. Working group leader reports
    2. Follow-on actions
     Meeting Recap, Action Items, Key Dates

    Attendance is open to the interested public but limited to space
availability. With the approval of the chairman, members of the public
may present oral statements at the meeting. Persons wishing to present
statements or obtain information should contact the person listed in
the FOR FURTHER INFORMATION CONTACT section. Members of the public may
present a written statement to the committee at any time.

    Issued in Washington, DC on September 1, 2016.
Mohannad Dawoud,
Management & Program Analyst, Partnership Contracts Branch, ANG-A17,
NextGen, Procurement Services Division, Federal Aviation
Administration.
[FR Doc. 2016-21403 Filed 9-2-16; 8:45 am]
 BILLING CODE 4910-13-P